Atea Pharmaceuticals Inc (NAS:AVIR)
$ 4.02 0.13 (3.34%) Market Cap: 339.38 Mil Enterprise Value: -171.79 Mil PE Ratio: 0 PB Ratio: 0.71 GF Score: 43/100

Atea Pharmaceuticals Inc AT-527 Clinical Data Update Call Transcript

Oct 19, 2021 / 12:30PM GMT
Release Date Price: $13.82 (-65.96%)
Operator

Good morning, ladies and gentlemen, and welcome to the Atea Pharmaceuticals A2 -- AT-527 Clinical Update Conference Call. (Operator Instructions) I would now like to turn the call over to Jonae Barnes, Senior Vice President of Investor Relations and Corporate Communications at Atea Pharmaceuticals. Please proceed.

Jonae R. Barnes
Atea Pharmaceuticals, Inc. - SVP of IR & Corporate Communications

Thank you, operator. Good morning, everyone, and welcome to Atea Pharmaceuticals AT-527 Clinical Update Conference Call.

This morning, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the slides that we will be reviewing today by going to the Investors section of our website at iratteapharma.com.

With me today from Atea are Dr. Jean-Pierre Sommadossi, Founder and CEO; Dr. Janet Hammond, Chief Development Officer; John Vavricka, Chief Commercial Officer; and Andrea Corcoran, CFO. They will all be available for the Q&A portion of today's call.

Before we begin the call,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot